ClinicalTrials.gov
public full text
Public Domain
Phase 4 Multicenter, Open-label Study on Efficacy and Safety of Apremilast in Moderate-to-severe Psoriasis
This study aims to evaluate the efficacy and safety of Apremilast tablets in patients with psoriasis over 32 weeks, through a multicenter, single-arm, open-label, phase 4 clinical trial.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- A Phase 3 Study in Participants With Moderate to Severe Psoriasis#855547
- A Phase 2, Multicenter Open-Label Extension (OLE) Study With ABT-122 in Active Psoriatic Arthritis Subjects Who Have Completed a Preceding Study M14-197#898423
- Systemic Treatment of Moderate-to-severe Psoriasis in Adults: Update of the French Guidelines#1093644
- Comparative Efficacy of Alpha Hydroxy Acids With and Without Nanocarriers Versus Calcipotriol Plus Betamethasone in Treatment of Plaque Psoriasis#914186
- The Leukotriene Modifier Or Corticosteroid or Corticosteroid-Salmeterol Trial#812713
Record · ID 897331
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive